
Peter Vadas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10946361/publications.pdf Version: 2024-02-01



DETED VADAS

#	Article	IF	CITATIONS
1	Platelet-Activating Factor, PAF Acetylhydrolase, and Severe Anaphylaxis. New England Journal of Medicine, 2008, 358, 28-35.	13.9	476
2	A Natural Disruption of the Secretory Group II Phospholipase A2 Gene in Inbred Mouse Strains. Journal of Biological Chemistry, 1995, 270, 22378-22385.	1.6	308
3	Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. Journal of Allergy and Clinical Immunology, 2013, 131, 144-149.	1.5	185
4	Detection of Peanut Allergens in Breast Milk of Lactating Women. JAMA - Journal of the American Medical Association, 2001, 285, 1746.	3.8	180
5	Pathogenesis of hypotension in septic shock. Critical Care Medicine, 1988, 16, 1-7.	0.4	129
6	Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. Biochemical Pharmacology, 1992, 44, 1165-1170.	2.0	123
7	Characterization of extracellular phospholipase A2 in rheumatoid synovial fluid. Life Sciences, 1985, 36, 579-587.	2.0	111
8	Platelets in the immune response: Revisiting platelet-activating factor in anaphylaxis. Journal of Allergy and Clinical Immunology, 2015, 135, 1424-1432.	1.5	99
9	Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock. Canadian Journal of Physiology and Pharmacology, 1983, 61, 561-566.	0.7	93
10	Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. Journal of Allergy and Clinical Immunology, 2009, 124, 307-314.e2.	1.5	92
11	Extracellular phospholipase A2 mediates inflammatory hyperaemia. Nature, 1981, 293, 583-585.	13.7	87
12	Purification of a Soluble Phospholipase A2 from Synovial Fluid in Rheumatoid Arthritis1. Journal of Biochemistry, 1986, 100, 1297-1303.	0.9	86
13	Inflammatory Effect of Intradermal Administration of Soluble Phospholipase A2 in Rabbits. Journal of Investigative Dermatology, 1986, 86, 380-383.	0.3	65
14	Regulation of the cellular expression of secretory and cytosolic phospholipases A2, and cyclooxygenase-2 by peptide growth factors. Biochimica Et Biophysica Acta - Molecular Cell Research, 1998, 1403, 47-56.	1.9	55
15	The release of phospholipase A2 from aggregated platelets and stimulated macrophages of sheep. Life Sciences, 1980, 26, 1721-1729.	2.0	51
16	Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine. Biochemical Pharmacology, 1997, 53, 1901-1907.	2.0	45
17	Effect of epinephrine on platelet-activating factor–stimulated human vascular smooth muscle cells. Journal of Allergy and Clinical Immunology, 2012, 129, 1329-1333.	1.5	41
18	Secretory Non-Pancreatic Phospholipase A2 and cyclooxygenase-2 Expression by Tracheobronchial Smooth Muscle Cells. FEBS Journal, 1996, 235, 557-563.	0.2	38

Peter Vadas

#	Article	IF	CITATIONS
19	The efficacy of anti-inflammatory agents with respect to extracellular phospholipase A2 activity. Life Sciences, 1982, 30, 155-162.	2.0	32
20	Heterogeneity in presentation and treatment of catamenial anaphylaxis. Annals of Allergy, Asthma and Immunology, 2013, 111, 107-111.	0.5	29
21	Methylene blue for the treatment of refractory anaphylaxis without hypotension. American Journal of Emergency Medicine, 2013, 31, 264.e3-264.e5.	0.7	29
22	Peanut Allergy: An Overview. Allergy, Asthma and Clinical Immunology, 2008, 4, 139.	0.9	28
23	Association of hyperphospholipasemia A2 with multiple system organ dysfunction due to salicylate intoxication. Critical Care Medicine, 1993, 21, 1087-1091.	0.4	25
24	Phospholipase A2 Activation is the Pivotal Step in the Effector Pathway of Inflammation. Advances in Experimental Medicine and Biology, 1990, 275, 83-101.	0.8	20
25	Comparison of group I and II soluble phospholipases A2 activities on phagocytic functions of human polymorphonuclear and mononuclear phagocytes. Inflammation, 1991, 15, 127-135.	1.7	19
26	Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy. Allergy, Asthma and Clinical Immunology, 2014, 10, 20.	0.9	18
27	Group II phospholipases A2 are indirectly cytolytic in the presence of exogenous phospholipid. Lipids and Lipid Metabolism, 1997, 1346, 193-197.	2.6	12
28	The platelet-activating factor pathway in food allergy and anaphylaxis. Annals of Allergy, Asthma and Immunology, 2016, 117, 455-457.	0.5	12
29	Plateletâ€activating factor acetylhydrolase is a biomarker of severe anaphylaxis in children. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2665-2676.	2.7	12
30	Inhibition of human group II phospholipase A2 by C-reactive protein in vitro. Journal of Lipid Mediators and Cell Signalling, 1995, 11, 187-200.	1.0	8
31	Reproducibility of Symptom Sequences Across Episodes of Recurrent Anaphylaxis. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 534-538.e1.	2.0	7
32	Potential Therapeutic Strategies for Severe Anaphylaxis Targeting Platelet-Activating Factor and PAF Acetylhydrolase. Current Treatment Options in Allergy, 2014, 1, 232-246.	0.9	6
33	Induction of circulating phospholipase A2by intravenous administration of recombinant human tumour necrosis factor. Mediators of Inflammation, 1992, 1, 235-240.	1.4	3
34	Anaphylaxis: Clinical features and mediator release patterns. Journal of Allergy and Clinical Immunology, 2013, 132, 1456-1457.	1.5	3
35	Cortisol response to corticotropin and survival in septic shock. Lancet, The, 1991, 337, 1230-1231.	6.3	1
36	Reply. Journal of Allergy and Clinical Immunology, 2013, 131, 1714-1715.	1.5	0

#	Article	IF	CITATIONS
37	Phospholipase A2 and the Pathogenesis of Multisystem Organ Failure in Experimental and Clinical Endotoxin Shock. , 1994, , 203-211.		0